OncoMatch/Clinical Trials/NCT06843889
A Phase II Study of Toripalimab Combined With Sequential Neoadjuvant Chemoradiotherapy in Patients With Esophageal Squamous Cell Carcinoma
Is NCT06843889 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies Toripalimab (240mg day1, Q3W*3cycle) for locally advanced esophageal squamous cell carcinoma.
Treatment: Toripalimab (240mg day1, Q3W*3cycle) — This was a single-center, open phase II clinical study. 34 patients with resectable local middle and advanced esophageal squamous cell carcinoma were treated with anti-PD-1 antibody combined with sequential chemoratherapy regimen: Phase I:Toripalimab (240mg day1, Q3W\*2cycle) + clinical routine chemotherapy regimen selected by the investigator; The second stage: Toripalimab (240mg day1, Q3W\*1cycle) + radiotherapy (intensity modulated radiotherapy, 40Gy/20F, 2Gy/F); Surgery was performed 4-6 weeks after completion, and subsequent treatment options were considered after surgery according to MDT discussion. According to the postoperative pathological results, the pathological complete response (pCR) and major response (MPR) were evaluated. The disease-free survival (DFS), overall survival (OS), 1 or 2 years survival rate and adverse reactions were recorded.
Check if I qualifyExtracted eligibility criteria
Cancer type
Esophageal Carcinoma
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: systemic therapy
Lab requirements
Blood counts
white blood cell ≥4.0×10^9/l, neutrophil ≥1.5×10^9/l, platelet ≥100.0×10^9/l, hemoglobin ≥90g/l; Serum albumin ≥2.8g/Dl
Kidney function
Serum creatinine ≤1.5 × ULN or creatinine clearance > 60 mL/min
Liver function
Total bilirubin ≤1.5 × ULN, ALT/AST/ AKP≤2.5 × ULN
Cardiac function
No severe cardiovascular disease, such as NYHA class 2 or higher heart failure, unstable angina, unstable arrhythmia, myocardial infarction or cerebrovascular accident within 6 months before enrollment
The function of vital organs meets the following requirements: white blood cell ≥4.0×10^9/l, neutrophil ≥1.5×10^9/l, platelet ≥100.0×10^9/l, hemoglobin ≥90g/l; Serum albumin ≥2.8g/Dl; Total bilirubin ≤1.5 × ULN, ALT/AST/ AKP≤2.5 × ULN; Serum creatinine ≤1.5 × ULN or creatinine clearance > 60 mL/min; There were no severe organic diseases.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify